Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK-TAP: JAK Inhibitor Dose Tapering in Rheumatoid Arthritis
NCT06687551Phase 4Recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2025
- Primary completion
- Apr 2029
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of baricitinib, filgotinib, tofacitinib oral solution and upadacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Proportion of patients still receiving a JAK-inhibitor at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
baricitinibfilgotinibtofacitinib oral solutionupadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06687551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687551.